KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBITDA (2019 - 2025)

GoodRx Holdings' EBITDA history spans 7 years, with the latest figure at $22.7 million for Q4 2025.

  • For Q4 2025, EBITDA rose 24.77% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $87.5 million, up 32.87%, while the annual FY2025 figure was $91.7 million, 30.34% up from the prior year.
  • EBITDA for Q4 2025 was $22.7 million at GoodRx Holdings, up from $14.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $26.8 million in Q2 2025 and bottomed at -$38.3 million in Q3 2023.
  • The 5-year median for EBITDA is $11.5 million (2021), against an average of $7.1 million.
  • The largest YoY upside for EBITDA was 552.38% in 2023 against a maximum downside of 1152.85% in 2023.
  • A 5-year view of EBITDA shows it stood at $11.8 million in 2021, then plummeted by 85.22% to $1.7 million in 2022, then tumbled by 1152.85% to -$18.3 million in 2023, then skyrocketed by 199.41% to $18.2 million in 2024, then rose by 24.77% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's EBITDA are $22.7 million (Q4 2025), $14.6 million (Q3 2025), and $26.8 million (Q2 2025).